Brands Capitalize on Creative with Advances in the Ad-Lib.io Platform
Ad-Lib.io, a Smartly.io company and a leading next-generation Creative Management Platform (CMP), announced today the release of the next generation of Personalize™, Ad-Lib.io’s award-winning cookieless platform for creative management, media alignment and creative intelligence all in one place. Personalize 2.0 delivers breakthrough capabilities to accelerate and scale campaign activation while ensuring brand governance and improved campaign addressability cross-channel.
As a result of these advances, advertisers are experiencing a range of ROAS benefits, including:
- 28% reduction in time required to link media and creative strategies in a single digital workspace,
- 4x faster campaign builds with on-brand assets, published and approved automatically,
- 85% fewer clicks to build personalized variants for every audience in their media plan, and
- Up to a week’s advance notice prior to the onset of campaign fatigue, thanks to AI-driven modeling, along with the creative data insights to tune performance at the variant level.
“Scaling campaigns significantly while comfortably reducing production time has been simply delightful,” said Barbara Piras, Group Head of Digital Marketing at TUI Group. “Adding Ad-Lib.io’s technology to our marketing workflow has opened a new world of creative possibilities I’m excited to explore in the future.”
“Our hyperlocal marketing strategy has been instrumental to our success, and Ad-Lib.io is a key partner in helping us scale our reach and creative effectiveness in record time,” said Dean Weaving, Director of Brand Media Operations at Deliveroo. “Their platform has brought our creative and media teams together at a high level of collaboration and coordination, time and time again. We look forward to continuing our work, leveraging their platform, to bring the same relevant, on-target advertising to a multitude of highly differentiated localities.”
“According to a recent WBR Insights survey, only 10% of advertisers felt that their creative and media teams were aligned. This disconnect leads to a number of inefficiencies and sub-optimal results, and it is a core challenge addressed by our platform,” said Oli Marlow Thomas, Ad-Lib.io Founder. “Our goal is to transform the creative production process into one that is easier, faster, more collaborative, data-advised and better aligned to media strategies.”
With Personalize 2.0, advertisers can now execute multi-market activations across channels in fewer steps, integrate with leading media platforms to instantly pull in target audiences and publish approved creatives while reducing the risk of creative rejection. Advertisers can also build targeted creative campaigns and test and learn strategies at scale in minutes, across display, video and social. AI can be leveraged at every step along the way, from asset cropping for quick and easy image editing across channels and formats, to fatigue alerts to prevent premature decline in campaign performance. Best of all, in-line performance reporting reduces the campaign optimization effort to just a few clicks.
Personalize 2.0 is immediately available. Click here for more information on Ad-Lib.io and the Smartly.io family of creative effectiveness capabilities.
About Ad-lib.io
Ad-Lib.io, a Smartly.io company, provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-LIb.io’s customers, including TUI, Estee Lauder, IG, Pizza Hut and other global brands.. Recently acquired by Smartly.io, Ad-Lib.io was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005295/en/
Contact information
Dina Magdovitz
smartly.io@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
